Niraparib, approved for BRCA1/2-mutated ovarian cancer, and Rucaparib, approved for ovarian and prostate cancers, are also under evaluation for the treatment of PDAC in patients with known DNA repair mutations [136,137,138]. Here, BRCA1 is linked to prostate carcinoma.